阿托伐他汀钙联合依折麦布治疗冠心病的效果分析

Effect Analysis of Atorvastatin Calcium Combined with Ezetimibe in Treatment of Coronary Heart Disease

目的:探讨阿托伐他汀钙联合依折麦布治疗冠心病的效果。方法:选取2020年2月—2022年2月北京市朝阳区崔各庄社区卫生服务中心收治的106例冠心病患者作为研究对象,根据随机数字表法分为对照组与观察组,各53例。对照组给予阿托伐他汀钙治疗,观察组在对照组基础上给予依折麦布治疗。比较两组血脂水平、心功能指标、治疗效果、不良反应发生情况。结果:治疗前,两组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)指标水平比较,差异无统计学意义(P>0.05);治疗后,观察组TG、TC、LDL-C水平低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05)。治疗前,两组每搏输出量(SV)、每分钟输出量(CO)、左室射血分数(LVEF)、脑钠肽(NT-ProBNP)水平比较,差异无统计学意义(P>0.05);治疗后,观察组SV、CO、LVEF水平高于对照组,NT-ProBNP水平低于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率高于对照组,差异有统计学意义(P=0.001)。观察组不良反应发生率低于对照组,差异有统计学意义(P=0.017)。结论:对冠心病患者采用阿托伐他汀钙片与依折麦布的联合用药方案,可明显改善其血脂水平与心功能,疗效确切,且安全性较好。

Objective:To investigate the effect of atorvastatin calcium combined with ezetimibe in the treatment of coronary heart disease.Methods:From February 2020 to February 2022,106 patients with coronary heart disease admitted to Cuigezhuang Community Health Service Center of Chaoyang District of Beijing were selected as the study subjects,and they were divided into control group and observation group according to the random number table method,with 53 cases in each group.The control group was treated with atorvastatin calcium,and the observation group was treated with ezetimibe on the basis of the control group.The blood lipid levels,cardiac function indicators,treatment effects,and adverse reactions of the two groups were compared.Results:Before treatment,there was no significant difference in the levels of total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C)and high-density lipoprotein cholesterol(HDL-C)between the two groups(P>0.05).After treatment,the levels of TG,TC and LDL-C in the observation group were lower than those in the control group,and the levels of HDL-C in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in stroke volume(SV),cardiac output(CO),left ventricular ejection fraction(LVEF),and N-terminal pro-brain natriuretic peptide(NT-ProBNP)between the two groups(P>0.05).After treatment,the levels of SV,CO and LVEF in the observation group were higher than those in the control group,and the levels of NT-ProBNP in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).The overall effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P=0.001).The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P=0.017).Conclusion:The combined application of atorvastatin calcium tablets and ezetimibe in the patients with coronary heart disease can obviously improve the blood lipid level and cardiac function,with definite efficacy and good safety.